|
September 15, 2010
Positive Phase 2 Data for RLY5016 Presented in Late-Breaker Session at Heart Failure Society of America Meeting
September 13, 2010
Relypsa Raises $70 Million in Series B - Financing; Funds to Support Late-Stage Development of RLY5016; New Board Members Announced
August 29, 2010
ESC 2010: Hot Line I: New oral potassium binder lowers potassium levels in patients with heart failure and heart failure with chronic kidney disease
June 16, 2010
Relypsa Initiates Open-Label Phase 2 Clinical Study of RLY5016 for the Management of Hyperkalemia
June 16, 2010
Relypsa Appoints Claire J. Lockey Vice President, Regulatory Affairs
|
